This poster outlines how Ncardia builds iPSC-derived cell models as a manufacturing process rather than a short-term lab activity, enabling reproducible, high-volume drug screening over multi-year timelines.
Download it now for a closer look at:
How large-scale, stirred-tank bioreactor manufacturing enables consistent iPSC-derived cell supply across years, not months
Process control strategies using defined CPPs, CMAs, and CQAs to maintain stable phenotype, functionality, and assay performance at scale
Data demonstrating reproducibility across multiple iPSC-derived models, including cardiomyocytes, 3D cardiac microtissues, and microglia
Why treating iPSC models as infrastructure reduces revalidation, operational risk, and variability in high-throughput screening programs
Whether you are running pilot screens or multi-year discovery programs, Ncardia’s iPSC-derived models provide a scalable and reproducible foundation for high-throughput screening and decision-making.